Site Editor

Thomas Flaig, MD


Thomas Flaig, MD, on the Role of Antibody-Drug Conjugates in Advanced Urothelial Cancer

Posted: Wednesday, May 10, 2023

Thomas Flaig, MD, of Anschutz Medical Campus, Aurora, Colorado, discusses the clinical settings in which two antibody-drug conjugates—enfortumab vedotin-ejfv and sacituzumab govitecan-hziy—are being used in the treatment of advanced urothelial cancer. Data on the use of these agents alone in combination with immunotherapy are emerging, he added.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.